Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.57 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5191016 | 0.94 | HDAC1 (0.72) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL30989338 | 0.94 | HDAC1 (0.72) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL300007 | 0.92 | TAAR1 (0.62) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL5717704 | 0.90 | LMNA (0.56) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL5717516 | 0.87 | HDAC1 (0.63) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL15931848 | 0.86 | HDAC1 (0.62) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL9150165 | 0.84 | TAAR1 (0.53) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL108050 | 0.82 | CALM1 (0.72) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL4698724 | 0.82 | TSHR (0.53) | HDAC1HDAC3HDAC6HDAC2TAAR1 | |
| SCHEMBL11697156 | 0.82 | HDAC1 (0.69) | HDAC1HDAC3HDAC6HDAC2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040410-A | Preparation method of piperonylethylamine | 湖北石河医药科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-116715652-A | Preparation method of key intermediate piperonylethylamine of berberine | 迪庆顺源生物有限公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | HDAC1 226/4885HDAC3 259/4885HDAC6 140/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | HDAC1 226/4885HDAC3 259/4885HDAC6 140/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | HDAC1 193/4885HDAC3 228/4885HDAC6 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.